Oric Pharmaceuticals, Inc. Jefferies Global Healthcare Conference in London - ORIC PHARMACEUTICALS INC
Financial Performance:
- Cash Position: Ended Q3 2025 with $345 million in cash and investments.
- Runway: Provides a fully burdened cash runway extending into the second half of 2028, covering costs for ongoing Phase 3 trials and anticipated future Phase 3 launches.
- Profitability/Margins: No revenue or profit margins reported as the company is in late-stage clinical development; the focus remains on drug development costs and trial execution.
- Debt: No mention of debt in the transcript; the company appears to be equity-funded with a strong liquidity position.
Guidance and Future Outlook:
- Rinzimetastat (Prostate): Top-line data expected for the Phase 3 "Himalayas 1" study in the first half of 2026 (enrollment targeting 16 months, study designed for faster readout with 95% power for 0.66 hazard ratio).
- Enozertinib (Lung): Phase 3 trials ("Redwood 1") for EGFR atypical and Exon 20 mutations planned to initiate in 2026, with potential to start earlier if data supports.
- Market Opportunity: Targeting two post-AR inhibitor populations (post-abiraterone and post-AR inhibitor) representing a $3.5 billion US market each; potential to expand into castration-sensitive prostate cancer (CSBC) for a $10 billion opportunity.
- Development Path: Plans to accelerate development into earlier lines of therapy (CSBC) if competitor data (Pfizer's Mevrometastat) validates the mechanism's efficacy and safety.
Business Segments and Product Lines:
- Rinzimetastat (PRC2 Inhibitor): Oral PRC2 EED inhibitor developed in combination with darolutamide for prostate cancer.
- Clinical Data: Demonstrates 60% 10-month landmark PFS in both post-abiraterone and post-AR inhibitor cohorts, comparable to Pfizer's data but with a significantly cleaner safety profile (reduced GI and hematologic toxicity).
- Differentiation: 20-hour half-life (vs. 4-hour for Pfizer's drug), lower dose (400mg vs. 1.8g daily), no CYP autoinduction, and minimal food effect.
- Enozertinib (EGFR Inhibitor): Oral drug targeting EGFR atypical mutations and Exon 20 mutations in lung cancer.
- Clinical Data: 84% overall response rate (ORR) and 70% intracranial response rate (IRR) in a heavily pre-treated population with brain metastases; 88% 6-month landmark PFS.
- Differentiation: Superior CNS penetration compared to non-brain-penetrant competitors; minimal EGFR wild-type related toxicity (e.g., liver enzyme elevations, anemia).
- Rinzimetastat (PRC2 Inhibitor): Oral PRC2 EED inhibitor developed in combination with darolutamide for prostate cancer.
Market and Competitive Landscape:
- Prostate Cancer Competition: Pfizer's Mevrometastat is the primary comparator; OREC expects top-line data in Q1 2026. J&J's RIPTAC (6143) showed early promise but requires further durability and safety data; no combination with AR inhibitors possible due to binding domain overlap.
- Lung Cancer Competition: Competitors include Amivantamab (J&J), Black Diamond, and Aravant; OREC differentiates via CNS efficacy and a safety profile lacking wild-type EGFR toxicities.
- Market Trends: Shift toward brain-penetrant therapies for lung cancer and combination therapies targeting epigenetic modifiers in prostate cancer; safety profile is the key driver for physician adoption (similar to the trajectory of apalutamide/darolutamide in the AR inhibitor space).
Risks and Challenges:
- Clinical Trial Readouts: Potential for Pfizer's Mevrometastat to result in a "near miss" (statistically significant but modest efficacy or safety issues) due to food effects, drug-drug interactions (CYP induction), or toxicities leading to dose reductions.
- Competitor Uncertainty: J&J's RIPTAC requires more data on durability and safety before OREC can consider combination strategies.
- Trial Execution: Maintaining enrollment and site activation for the 600-patient Himalayas 1 study; managing variability in physician choice control arms (AR switch vs. chemotherapy).
- Regulatory/Operational: Ensuring the "less pretreated" population in Phase 3 accurately reflects the efficacy seen in more heavily pre-treated Phase 2 cohorts.
Management Commentary and Tone:
- Tone: Highly confident and optimistic; management emphasizes the "dogma" in lung cancer favoring CNS-penetrant drugs and the clear safety differentiation of their prostate program.
- Confidence: Expresses near certainty that Pfizer will not result in a "big miss," while highlighting that any "near miss" scenarios (food effects, DDIs) do not apply to OREC's assets due to their superior pharmacokinetics.
- Strategic Focus: Aggressive pursuit of faster development timelines to capitalize on the validated PRC2 and CNS-penetrant mechanisms.
Analyst Questions and Answers:
- Q: How does Rinzimetastat differ pharmacologically from Pfizer's Mevrometastat?
- A: Rinzimetastat targets the EED subunit (allosteric inhibition) with a 20-hour half-life and no CYP autoinduction, allowing lower dosing (400mg vs. 1.8g) and a cleaner safety profile compared to Pfizer's EZH2-targeted, shorter half-life drug.
- Q: What does the delay in Pfizer's top-line data imply?
- A: Likely indicates fewer events (treatment arm doing well), a skew in the control arm toward less active AR switches, or high censoring; statistically, a "big miss" is ruled out.
- Q: What would constitute a "near miss" for OREC if Pfizer misses?
- A: A modest hazard ratio or efficacy signal that is statistically significant but not "game-changing"; however, OREC believes their differentiation prevents direct negative read-through from Pfizer's potential near miss.
- Q: How do you view J&J's RIPTAC data?
- A: Impressive early data (PSA 50/90) but requires longer follow-up on durability and safety (liver/kidney tox) before potential combination strategies can be considered.
- Q: How does Rinzimetastat differ pharmacologically from Pfizer's Mevrometastat?
Other Key Points:
- Trial Design: OREC's Phase 3 "Himalayas 1" mirrors Pfizer's design (600 patients, radiographic PFS primary endpoint) to allow direct side-by-side comparison of efficacy and safety.
- Safety Profile: OREC highlights that their combination with darolutamide avoids CYP induction issues seen with enzalutamide (used by Pfizer), reducing variability in drug exposure.
- Funding Status: The $345 million cash position is sufficient to fund the company past the critical data readouts for both major programs, eliminating near-term financing risk.
- Company
- ORIC PHARMACEUTICALS INC
- Keywords
- ORIC PHARMACEUTICALS INC